Trevi Therapeutics, Inc. — Director's Dealing 2019

May 7, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Trevi Therapeutics, Inc. (TRVI)
CIK: 0001563880
Period of Report: 2019-05-07

Reporting Person: SCIASCIA THOMAS (Chief Medical Officer, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	176606	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (15549)		Direct
Series C Preferred Stock	$		Common Stock (1565)		Direct
Employee Stock Option (right to buy)	$3.14	2023-07-10	Common Stock (12257)		Direct
Employee Stock Option (right to buy)	$3.23	2024-01-22	Common Stock (11289)		Direct
Employee Stock Option (right to buy)	$2.19	2024-07-01	Common Stock (59354)		Direct
Employee Stock Option (right to buy)	$1.43	2024-11-24	Common Stock (48001)		Direct
Employee Stock Option (right to buy)	$1.43	2025-05-14	Common Stock (2631)		Direct
Employee Stock Option (right to buy)	$3.33	2027-12-19	Common Stock (7895)		Direct

Footnotes

F1: The Series A Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series A Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date.

F2: The Series C Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series C Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date.

F3: This option was granted on July 11, 2013. The 12,257 shares of common stock underlying the option vested as to 25% of the shares on July 11, 2014 and as to the remaining 75% of the shares in equal monthly installments thereafter through July 11, 2017.

F4: This option was granted on January 23, 2014. The 11,289 shares of common stock underlying the option vested as to 25% of the shares on January 23, 2015 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 23, 2018.

F5: This option was granted on July 2, 2014. The 59,354 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.

F6: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

F7: This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and are scheduled to vest as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.

F8: This option was granted on December 20, 2017. The 7,895 shares of common stock underlying the option vested as to 25% of the shares on December 20, 2018 and are scheduled to vest as to the remaining 75% of the shares in equal monthly installments thereafter through December 20, 2021.